Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Randomized, Multi-centric, Comparator-controlled Study of the Safety and Neutralizing Activity of a Human Monoclonal Antibody to Rabies (SII RMAb) Administered in Conjunction with Rabies Vaccine for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

X
Trial Profile

A Phase II/III, Randomized, Multi-centric, Comparator-controlled Study of the Safety and Neutralizing Activity of a Human Monoclonal Antibody to Rabies (SII RMAb) Administered in Conjunction with Rabies Vaccine for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-rabies monoclonal antibody (Primary) ; Anti-rabies monoclonal antibody (Primary) ; Rabies immune globulin; Rabies immune globulin; Rabies vaccine
  • Indications Rabies
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 15 Sep 2017 Results assessing safety and neutralizing activity of a human monoclonal antibody to rabies (sii rmab) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure, were published in the Clinical Infectious Diseases.
    • 15 Sep 2017 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
    • 10 Jul 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top